SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 3.41% Passive Stake in Protagenic Therapeutics

Armistice Capital, LLC and Steven Boyd have reported a 3.41% beneficial ownership stake in Protagenic Therapeutics, Inc., holding 240,000 shares as of December 31, 2024, as a passive investment.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed Amendment No. 4 to Schedule 13G regarding their beneficial ownership in Protagenic Therapeutics, Inc.
• As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 240,000 shares of Protagenic Therapeutics, Inc. Common Stock.
• This ownership represents 3.41% of the Issuer's outstanding Common Stock.
• The percentage is calculated based on 7,034,821 shares outstanding as of November 4, 2024, as reported in the Issuer's Form 10-Q filed on November 14, 2024.
• Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over these securities.
• Steven Boyd, as the managing member of Armistice Capital, is also deemed to beneficially own these shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: Neutral. This is a routine beneficial ownership filing (Schedule 13G Amendment), indicating a passive stake. It neither signals strong positive nor negative news for the company, as it's a disclosure of an existing or slightly adjusted holding rather than a new strategic investment or divestment.

Positives

• The filing indicates a continued passive investment by Armistice Capital and Steven Boyd in Protagenic Therapeutics, suggesting ongoing institutional interest.
• The investment is stated to be for passive purposes, indicating no immediate intent to influence or change control of the company.

Negatives

• The document, being a routine beneficial ownership report, does not inherently present negative information about Protagenic Therapeutics, Inc.

Risks

• The document is a beneficial ownership report (Schedule 13G) and does not contain information regarding specific business, operational, or financial risks of Protagenic Therapeutics, Inc.

Future Outlook

The document is a beneficial ownership filing and does not contain forward-looking statements or guidance from the issuer or the reporting persons regarding the issuer's future performance or strategic direction.

Management Comments

• Steven Boyd, as the managing member of Armistice Capital, LLC, certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This Schedule 13G filing is a routine disclosure by an institutional investor, Armistice Capital, LLC, and its managing member, Steven Boyd, regarding their passive stake in Protagenic Therapeutics, Inc. Such filings are common in the investment industry, reflecting portfolio adjustments or ongoing passive holdings by investment funds. It does not provide specific insights into broader industry trends or competitive landscape beyond the fact that an investment firm holds a stake in a company within the biotechnology or pharmaceutical sector (implied by 'Therapeutics').

Comparison to Industry Standards

• This document is a beneficial ownership filing and does not provide financial or operational results that can be compared to industry benchmarks or specific comparable companies or projects. It solely reports a passive ownership stake.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant passive institutional holding, which can offer some level of confidence or insight into institutional interest in the company.
• Management: Awareness of a passive institutional investor holding a stake, but no direct impact on operations or strategy is implied by this filing.

Next Steps

• The document does not mention any specific future actions, events, or milestones for Protagenic Therapeutics, Inc. or the reporting persons beyond the ongoing passive investment.

Key Dates

Keywords

Protagenic Therapeutics, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Passive Investment, SEC Filing